MET-dependent solid tumours—molecular diagnosis and targeted therapy
Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
J Fu, X Su, Z Li, L Deng, X Liu, X Feng, J Peng - Oncogene, 2021 - nature.com
This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …
[HTML][HTML] Targeting MET in lung cancer: will expectations finally be MET?
The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon
skipping, deletion of the juxtamembrane domain containing the CBL E3-ubiquitin ligase …
skipping, deletion of the juxtamembrane domain containing the CBL E3-ubiquitin ligase …
HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers
Cancer is a major cause of death worldwide. MET tyrosine kinase receptor [MET, c-MET,
hepatocyte growth factor (HGF) receptor] pathway activation is associated with the …
hepatocyte growth factor (HGF) receptor] pathway activation is associated with the …
Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
Breast cancer is a heterogeneous disease, affecting over 3.5 million women worldwide, yet
the functional role of cis-regulatory elements including super-enhancers in different breast …
the functional role of cis-regulatory elements including super-enhancers in different breast …
Molecular pathology of primary non-small cell lung cancer
DI Suster, M Mino-Kenudson - Archives of medical research, 2020 - Elsevier
Lung carcinoma is one of the most common human cancers and is estimated to have an
incidence of approximately 2 million new cases per year worldwide with a 20% mortality …
incidence of approximately 2 million new cases per year worldwide with a 20% mortality …
[HTML][HTML] Molecular pathways and therapeutic targets in lung cancer
E Shtivelman, T Hensing, GR Simon, PA Dennis… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Lung cancer is still the leading cause of cancer death worldwide. Both histologically and
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …
[HTML][HTML] EGFR-TKI resistance in NSCLC patients: mechanisms and strategies
Y Lin, X Wang, H Jin - American journal of cancer research, 2014 - ncbi.nlm.nih.gov
The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …
plays a critical role in the initiation and development of malignant tumors via modulating …
Racial differences in cancer susceptibility and survival: more than the color of the skin?
BC Özdemir, GP Dotto - Trends in cancer, 2017 - cell.com
Epidemiological studies point to race as a determining factor in cancer susceptibility. In US
registries recording cancer incidence and survival by race (distinguishing 'black versus …
registries recording cancer incidence and survival by race (distinguishing 'black versus …